Shire PLC
 (SHPG)

- NASDAQ
What's your position on ?
Bullish
Bearish
Why are you ish?
Skip
Post
You voted ish on Vote again
Posts appear on the My Feed page of subscribers to this ticker
Last vote:
  • Today, 12:28 PM
    • Intercept Pharmaceuticals (ICPT +21.9%) jumps on modest volume in apparent response to yet another rumor of a possible sale. In December, shares spiked on the rumor that Shire plc (SHPG +4.3%) was interested, but it took out Baxalta instead.
    • Its lead product candidate is obeticholic acid (OCA), under development for the treatment of primary biliary cirrhosis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis and biliary atresia.
    • The supposed allure for potential suitors is NASH, a blockbuster opportunity for the first mover. OCA flunked a Japan-based Phase 2 study in NASH, however. The FDA's action date for its review of the company's NDA for PBC is February 29.
    • Previously: Intercept Pharma's NASH candidate flunks mid-stage study; shares off 15% premarket (Oct. 28, 2015)
    • Previously: Intercept Pharma's obeticholic acid NDA for PBC gets Priority Review; PDUFA date is February 29 (Aug. 31, 2015)
    | Today, 12:28 PM | 6 Comments
  • Today, 7:38 AM
    • Gilead Sciences (NASDAQ:GILD) initiated with Outperform rating and $120 (37% upside) price target by Oppenheimer.
    • CareDx (NASDAQ:CDNA) initiated with Buy rating and $12 (137% upside) price target by Janney Capital.
    • Shire plc (NASDAQ:SHPG) initiated with Neutral rating by Guggenheim.
    • Ultragenyx Pharmaceutical (NASDAQ:RARE) initiated with Buy rating and $104 (95% upside) price target by H.C. Wainwright.
    • Depomed (NASDAQ:DEPO) initiated with Buy rating and $22 (38% upside) price target by UBS.
    • ACADIA Pharmaceuticals (NASDAQ:ACAD) initiated with Buy rating and $40 (128% upside) price target by Bank of America.
    • Leerink restarts coverage on eight stocks: four Outperforms: Alexion Pharmaceuticals (NASDAQ:ALXN); Regeneron Pharmaceuticals (NASDAQ:REGN); Vertex Pharmaceuticals (NASDAQ:VRTX) and Gilead Sciences (GILD); four Market Performs: Celgene (NASDAQ:CELG); Biogen (NASDAQ:BIIB); Medivation (NASDAQ:MDVN) and Amgen (NASDAQ:AMGN).
    • TESARO (NASDAQ:TSRO) initiated with Buy rating by Lake Street.
    • AbbVie (NYSE:ABBV) initiated with Outperform rating by William Blair.
    • Seattle Genetics (NASDAQ:SGEN) upgraded to Buy with $38 (41% upside) price target by Cantor Fitzgerald.
    • Shire plc (SHPG) upgraded to Outperform with price target of $240 (59% upside) by RBC.
    • Amedisys (NASDAQ:AMED) upgraded to Outperform with $40 (15% upside) price target by Oppenheimer.
    • Smith & Nephew (NYSE:SNN) downgraded to Neutral from Buy by UBS. Price target lowered to 1,100p (4% upside) from 1,250p.
    • Quidel (NASDAQ:QDEL) downgraded to Hold from Buy by Canaccord. Price target lowered to $18 (18% upside) from $22.
    • BioCryst Pharmaceuticals (NASDAQ:BCRX) downgraded Neutral from Overweight by JP Morgan. Price target lowered to $5 (201% upside) from $16.
    | Today, 7:38 AM | 6 Comments
  • Yesterday, 9:18 AM
    • Shire plc (NASDAQ:SHPG) Q4 results ($M): Total Revenues: 1,715.7 (+8.9%); Product Sales: 1,623.7 (+8.2%).
    • Key Product Sales: Vyvanse: 453.3 (+18.2%); Lialda/Mezavant: 201.4 (+9.0%); Elaprase: 147.1 (+2.7%); Cinryze: 143.3 (+0.6%), Firazyr: 125.2 (+22.9%).
    • Net Income: 280.6 (-87.1%); Non-GAAP Net Income: 587.6 (+13.2%); EPS: 0.473 (-87.1%); Earnings per ADS: 0.1419 (-87.1%); Non-GAAP Earnings per ADS: 0.2971 (+12.8%); CF Ops: 761.8 (-70.2%).
    • 2016 Guidance: Product Sales Growth: 11 - 14%; Non-GAAP Earnings/ADS Growth: 7 - 10%.
    • Shares are up 3% premarket on increased volume.
    | Yesterday, 9:18 AM
  • Yesterday, 8:31 AM
    • Shire PLC (NASDAQ:SHPG): FY15 EPADS of $11.68
    • Revenue of $6.4B (+6.3% Y/Y)
    • Shares +3% PM
    • Press Release
    | Yesterday, 8:31 AM
  • Wed, Feb. 10, 5:30 PM
    | Wed, Feb. 10, 5:30 PM | 26 Comments
  • Thu, Feb. 4, 4:33 PM
    | Thu, Feb. 4, 4:33 PM
  • Tue, Feb. 2, 8:02 AM
    | Tue, Feb. 2, 8:02 AM | 16 Comments
  • Mon, Jan. 25, 7:57 AM
    • Shire plc (NASDAQ:SHPG) resubmits its New Drug Application (NDA) to the FDA seeking clearance of lifitegrast for the treatment of signs and symptoms of dry eye disease in adults. It received a Complete Response Letter (CRL) in October 2015 after it filed the original NDA. Among the issues cited by the agency was the requirement for an additional trial.
    • The new filing includes data from the Phase 3 OPUS-3 study as well as additional information related to product quality.
    • Lifitegrast binds to a cell surface protein on white blood cells called integrin lymphocyte function-associated antigen-1 (LFA-1) which blocks its interaction with ICAM-1, an adhesion molecule that is over-expressed in corneal and conjunctival tissues in dry eye disease. LFA-1/ICAM-1 interaction leads to the secretion of pro-inflammatory cytokines associated with dry eye disease.
    • Previously: Mixed results for Shire in late stage lifitegrast trial (Dec. 6, 2013)
    • Previously: Shire to refile lifitegrast NDA in Q1 (Oct. 19, 2015)
    | Mon, Jan. 25, 7:57 AM
  • Fri, Jan. 22, 9:47 AM
    • Shire plc (SHPG +3.1%) completes its $5.9B acquisition of (DYAX), whose shareholders will receive $37.30 per share in cash plus potentially $4 more via a non-tradable contingent value right (CVR) related to the regulatory clearance of DX-2930 for the treatment of hereditary angioedema (HAE). A Phase 3 study should be completed in December.
    • Previously: Shire buys Dyax for $5.9B in cash (Nov. 2, 2015)
    | Fri, Jan. 22, 9:47 AM | 7 Comments
  • Wed, Jan. 20, 3:46 PM
    • Tomorrow is the special meeting of (DYAX +0.1%) shareholders at which they will vote on Shire's (SHPG -1.7%) $37.30 per share bid ($5.9B). Overwhelming support is expected.
    • Previously: Shire buys Dyax for $5.9B in cash (Nov. 2, 2015)
    | Wed, Jan. 20, 3:46 PM
  • Fri, Jan. 15, 12:10 PM
    • Varian Medical Systems (VAR -1.4%) assumed (analyst transition) with Outperform rating and $91 (21% upside) price target by Barrington Research.
    • Sucampo Pharmaceuticals (SCMP -6.5%) initiated with Sell rating and $7 (45% downside risk) price target by Empire.
    • Shire plc (SHPG -1.1%) upgraded to Outperform from Neutral by Credit Suisse. Price target reduced to ₤50 from ₤54.
    • Mead Johnson Nutrition (MJN -1.3%) downgraded to Neutral from Overweight by JP Morgan. Price target lowered to $77 (13% upside) from $85.
    | Fri, Jan. 15, 12:10 PM
  • Thu, Jan. 14, 5:40 PM
    • Top gainers, as of 5.25 p.m.: AU +5.5%. SBGL +3.8%. TS +3.2%. TVIX +2.8%. CB +2.4%.
    • Top losers, as of 5.25p.m.: MT -5.2%. CBD -5.2%. ARRS -4.6%. INTC -4.3%. SHPG -4.0%.
    | Thu, Jan. 14, 5:40 PM
  • Tue, Jan. 12, 5:37 PM
    • Top gainers, as of 5.25 p.m.: AU +8.0%. MET +7.1%.
    • Top losers, as of 5.25p.m.: FXCM -8.6%. AKS -3.8%. SGYP -3.8%. F -3.7%. SHPG -2.1%.
    | Tue, Jan. 12, 5:37 PM
  • Tue, Jan. 12, 9:15 AM
    | Tue, Jan. 12, 9:15 AM
  • Mon, Jan. 11, 7:36 AM
    • It's official. Shire plc (NASDAQ:SHPG) acquires Baxalta (NYSE:BXLT) for $45.57 per share ($32B). Under the terms of the deal, Baxalta shareholders will receive $18 per share in cash plus 0.1482 Shire ADS. The deal represents a 13.9% premium to Baxalta's closing price on Friday. The transaction should close by mid-year.
    • BXLT is up 4% premarket while SHPG is up 1%.
    • SA Contributor Chris DeMuth, whose Rangeley Capital has a significant stake in Baxalta, says, "We support the transaction and think it will be a successful deal for both companies." Rangeley's Andrew Walker adds, "I think the deal makes plenty of sense. [It] is full and fair and there are substantial synergies to be had from cost cutting and tax improvement. Both sets of shareholders should be very happy."
    • Previously: Shire to announce Baxalta deal as early as Monday (Jan. 7)
    • Previously: Shire sweetens Baxalta bid, deal imminent (Dec. 22, 2015)
    | Mon, Jan. 11, 7:36 AM | 51 Comments
  • Thu, Jan. 7, 3:35 PM
    | Thu, Jan. 7, 3:35 PM | 19 Comments
Company Description
Shire PLC is a specialty biopharmaceutical company that focuses on developing and marketing specialty medicines that address unmet patient needs.